XML 104 R2.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 27, 2019
Dec. 28, 2018
 [1]
Current assets:    
Cash and cash equivalents $ 242,317 $ 314,775
Short-term investments 518,350 378,559
Trade receivables, net 169,788 162,771
Other receivables 13,801 16,056
Inventory, net 13,366 9,838
Prepaid expenses and other current assets 14,490 15,017
Total current assets 972,112 897,016
Long-term investments 486,763 157,187
Long-term restricted cash and investments 1,000 1,100
Property and equipment, net 49,467 50,897
Operating lease right-of-use assets 17,735 5,867
Deferred tax assets, net 186,836 244,111
Goodwill 63,684 63,684
Other long-term assets 7,268 2,424
Total assets 1,784,865 1,422,286
Current liabilities:    
Accounts payable 8,352 10,901
Accrued compensation and benefits 31,713 32,142
Accrued clinical trial liabilities 30,330 18,231
Rebates and fees due to customers 16,782 14,954
Accrued collaboration liabilities 7,973 7,419
Other current liabilities 45,919 21,825
Total current liabilities 141,069 105,472
Long-term portion of lease liabilities 23,705 12,178
Long-term portion of deferred revenue 15,399 15,897
Other long-term liabilities 975 1,286
Total liabilities 181,148 134,833
Commitments
Stockholders’ equity:    
Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 303,776,032 and 299,876,080 at September 30, 2019 and December 31, 2018, respectively 304 300
Additional paid-in capital 2,228,839 2,168,217
Accumulated other comprehensive income (loss) 2,668 (701)
Accumulated deficit (628,094) (880,363)
Total stockholders’ equity 1,603,717 1,287,453
Total liabilities and stockholders’ equity $ 1,784,865 $ 1,422,286
[1]
The Condensed Consolidated Balance Sheet as of December 31, 2018 has been derived from the audited financial statements as of that date.